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Abstract 
Background/Aims: Peritoneal fibrosis is a serious 
complication of peritoneal dialysis (PD). It has been 
reported that administration of mizoribine, an effective 
immunosuppressant, ameliorated renal fibrosis in a rat 
model of unilateral ureteral obstruction. We therefore 
examined the effects of mizoribine in an experimental 
model of peritoneal fibrosis. 
Methods: Twenty-four rats were given a daily 
intraperitoneal injection of chlorhexidine gluconate and 
ethanol dissolved in saline. The rats were divided into 
three groups (n=8 per group) that received either vehicle 
or mizoribine at a dose of 2 mg/kg or 8 mg/kg once a day. 
Twenty-eight days after the start of the treatments the 
rats were sacrificed and peritoneal tissue samples 
collected. Macrophage infiltration (ED1), myofibroblast 
accumulation (α-smooth muscle actin: SMA) and 
expression of type III collagen, transforming growth 
factor (TGF)-β and monocyte chemotactic protein-1 
(MCP-1) were examined by immunohistochemistry.  
Results: Mizoribine significantly suppressed 
submesothelial zone thickening and reduced macrophage 
infiltration. Mizoribine also reduced collagen III+ area 
and decreased the number of α-SMA+, TGF-β+ and 
MCP-1+ cells. The magnitude of the changes observed 
was dose-dependent.  
Conclusion: The administration of mizoribine 
prevented the progression of peritoneal fibrosis in this 
rat model. Mizoribine may represent a novel therapy 
for peritoneal sclerosis in patients undergoing 
long-term PD. 
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Introduction 
Peritoneal dialysis (PD) has been used for more than 
two decades as an attractive treatment for end-stage 
kidney disease. However, long-term PD treatment is 
associated with histopathological alterations in the 
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peritoneum [1]. Continuous exposure to bioincompatible 
dialysis fluids and repeated episodes of bacterial 
peritonitis play a major role in the alteration of peritoneal 
function and structure that occurs with time [2, 3]. The 
characteristic pathologic findings in the peritoneum of 
patients on long-term continuous ambulatory peritoneal 
dialysis (CAPD) therapy include marked peritoneal 
fibrosis with marked accumulation of collagen and loss 
of peritoneal mesothelial cells [4]. Indeed, a minority of 
patients may develop the serious complication of 
encapsulating peritoneal sclerosis (EPS) that is 
associated with a high mortality and characterized by 
severe progressive peritoneal fibrosis [5]. Therapeutic 
strategies for EPS are limited and include the appropriate 
use of steroids [6]. However, there is no experimental 
model for peritoneal fibrosis that is similar to the fibrosis 
that develops in patients on CAPD. 
Suga et al. developed an experimental model of 
peritoneal fibrosis in rats induced by the peritoneal 
injection of chlorhexidine gluconate (CG) [7]. 
CG-induced peritoneal fibrosis in rats is very similar to 
that seen in patients with EPS as many of the pathologic 
findings in the peritoneum of CAPD patients including 
the increased expression of type III collagen, α-smooth 
muscle actin (α-SMA) and macrophage infiltration were 
also observed in the peritoneum of animals injected with 
CG [8].  
Mizoribine is an imidazole nucleoside isolated from 
Eupenicillium brefeldianum and is an orally administered 
immunosuppressive agent. Mizoribine inhibits the 
conversion of inosine 5'-nucleotide to guanosine 
5'-nucleotide in the purine nucleotide biosynthetic 
pathway and has similar immunosuppressive effects 
upon both humoral and cellular immunity to 
mycophenolate mofetil (MMF) [9, 10, 11]. The efficacy 
of this agent has been demonstrated in patients with 
diverse conditions including renal transplant recipients 
[12] and patients with rheumatoid arthritis [13], Sjögren's 
syndrome [14], lupus nephritis [15] and primary 
nephrotic syndrome [16]. Moreover, the incidence of 
adverse effects including myelosuppression, 
hepatotoxicity and nephrotoxicity is lower with this drug 
than other immunosuppressive agents. Furthermore, 
recent studies have demonstrated that mizoribine 
improves renal tubulointerstitial fibrosis in unilateral 
ureteral obstruction (UUO) in the rat [17] in a 
dose-dependent manner [18]. 
In this study, we examined the therapeutic efficacy of 
mizoribine in a rat model of peritoneal fibrosis induced 
by the administration of CG.  
 
 
Methods 
Animals 
Fifty-two Wistar rats weighing 190 to 200 g were 
obtained from Charles River Laboratories Japan 
(Yokosuka, Japan). The animals were housed in the 
animal facility of Hiroshima University with free access 
to food and water. The Institutional Animal Care and Use 
Committee at Hiroshima University (Hiroshima, Japan) 
approved all the animal protocols and the experiments 
were performed in accordance with the National 
Institutes of Health Guidelines on the use of Laboratory 
Animals.  
 
Experimental protocol 
Peritoneal fibrosis was induced by the intraperitoneal 
injection of 0.1% chlorhexidine gluconate (CG) in 15% 
ethanol dissolved in saline as described previously [19]. 
Briefly, rats received a daily intraperitoneal injection of 
0.1% CG in 15% ethanol dissolved in 2 mL of saline for 
a period of 28 days. The intraperitoneal injection of CG 
was performed under anesthesia with isoflurane in order 
to ensure the accuracy of the injection. Intraperitoneal 
injections of CG were performed in the left portion of the 
abdomen, whereas the right portion of the peritoneum 
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was processed for histological evaluation in order to 
avoid mechanical damage of the peritoneum caused by 
repeated injections confounding the findings. 
The rats were divided into three groups that received 
either: (1) vehicle buffer (CG + vehicle group, N=8), (2) 
mizoribine at 2 mg/kg body weight (CG + 2 mg 
mizoribine group, N=8), (3) mizoribine at 8 mg/kg body 
weight (CG + 8 mg mizoribine group, N=8).  
Mizoribine (Asahi Kasei Pharma Corporation, Tokyo, 
Japan) was dissolved in 0.5 ml of distilled water and 
administered by daily oral gavage just before the CG 
injection. Control rats received a daily intraperitoneal 
injection of vehicle only (15% ethanol dissolved in 2 ml 
of saline) for 28 days (control group, N=8). Rats were 
killed 28 days after starting CG injection and the parietal 
peritoneal tissues were carefully dissected prior to 
fixation in 10% formalin and embedding in paraffin.  
 
Histological analysis 
Formalin-fixed, paraffin-embedded sections (4 μm) 
were stained with hematoxylin and eosin (H&E) for light 
microscopic observation. Cross-sections of the 
abdominal wall were examined and the thickness of the 
submesothelial collagenous zone above the abdominal 
muscle layer was defined as the peritoneal thickness [20]. 
The extent of peritoneal thickening was determined by 
analysis of digitized images using image analysis 
software NIS-Elements D (Nikon Corporation, Tokyo, 
Japan). The image was transformed into a matrix of 1280 
× 960 pixels and viewed at ×100 magnification. We 
selected a width of 840 μm in the examined field under 
the microscope and measured the area of the 
submesothelial layer within this selected width. For each 
sample, eight such areas were selected and the average 
area of the submesothelial layer was determined. 
 
Immunohistochemistry analysis 
Immunohistochemical analyses were performed using 4 
μm tissue sections as described previously [21, 22]. The 
following primary antibodies were used: (1) mouse 
monoclonal anti-rat ED1 antibody as a macrophage 
marker (1:200 dilution, MCA341R; Serotec, Oxford, 
UK ); (2) polyclonal rabbit anti-rat type III collagen 
antibody (1:500 dilution, AB757P; Chemicon 
International Inc., Temecula, CA, USA); (3) mouse 
monoclonal anti-α-smooth muscle actin (α-SMA) 
(1:1000 dilution, A2547; Sigma, St Louis, MO, USA); 
(4) polyclonal rabbit anti-mouse TGF-β1 antibody 
(1:1000 dilution, sc-146; Santa Cruz, CA, USA); (5) 
polyclonal rabbit anti-rat monocyte chemotactic 
protein-1 (MCP-1) antibody (1:250 dilution, FL-148; 
Santa Cruz, CA, USA). Tissue sections were placed in 
0.01M citrate buffer (pH 6.0) and heated for 10 minutes 
in a microwave oven. This treatment was used for ED1, 
TGF-β1, and MCP-1 staining. Sections were blocked in 
5% fetal calf serum (FCS), 5% bovine serum albumin 
(BSA) and 10% normal goat serum in 
phosphate-buffered saline (PBS) for 60 minutes and then 
incubated overnight at 40C with primary antibody diluted 
in 10% normal goat serum and 5% normal rat serum. 
After washing, endogenous peroxidase activity was 
blocked by incubating tissue sections in 0.6% H2O2 in 
methanol for 20 min. For ED1 and  α-SMA 
immunostaining, tissue sections were incubated with 
goat anti-mouse immunoglobulin-G (IgG) conjugated 
with horseradish peroxidase (HRP, P0447; DAKO, 
Glostrup, Denmark, diluted 1/50) for 45 minutes at room 
temperature followed by a complex of HRP-conjugated 
mouse anti-HRP IgG (P0850; DAKO, diluted 1/50) for 
45 minutes at room temperature. For type III collagen 
and MCP-1 immunostaining, tissue sections were 
incubated with goat anti-rabbit IgG conjugated with HRP 
(P0448; DAKO, diluted 1/50) for 45 minutes at room 
temperature followed by a complex of HRP-conjugated 
rabbit anti-HRP IgG (Z0113; DAKO diluted 1/50) for 45 
minutes at room temperature. Immunostaining for 
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TGF-β1 was conducted using the Vectastain ABC Elite 
reagent kit (Vector Labs, Burlingame, CA, USA) 
according to the manufacturer’s protocol. Goat 
anti-rabbit IgG (1:250 dilution, 65-6140; ZYMED, 
Carlsbad, CA, USA) was used as a secondary antibody. 
Specific antibody binding was detected by color 
development following reaction with H2O2 and 3-3 
diaminobenzidine tetrahydrochloride. In each peritoneal 
sample, the numbers of ED1 positive cells, α-SMA 
positive cells, TGF-β positive cells and MCP-1 positive 
cells were counted in 10 fields (×400 magnification). In 
order to assess the area positive for type III collagen 
immunostaining, the image files (1280 × 960) at ×200 
magnification were analyzed using Lumina Vision 
software (Mitani, Fukui, Japan). The positive area was 
shown as the mean of diaminobenzidine positive pixel 
values obtained from five image files in each section. 
Two color immunostaining was used to detect 
colocalisation of ED1 and TGF-β. After staining for 
TGF-β and development with diaminobenzidine to give a 
brown color, the sections were placed in 0.01M citrate 
buffer (pH 6.0) and heated for 10 minutes in a 
microwave oven. The sections were then blocked as 
described above, incubated overnight at 4°C with the 
monoclonal anti-ED1 antibody and incubated further 
with goat anti-mouse HRP for 45 minutes at room 
temperature. This was followed by incubation for 45 
minutes at room temperature in a complex of 
HRP-conjugated mouse anti-HRP IgG and development 
with Vector SG to give a blue/gray color. 
 
Pharmacokinetic analysis 
Twenty female Wistar rats weighing 190 to 200g were 
used for the pharmacokinetic analysis. Rats were divided 
into two groups with 10 rats receiving mizoribine at 2 
mg/kg body weight by oral gavage (2 mg mizoribine 
group) and the remaining 10 rats receiving mizoribine at 
8 mg/kg body weight by oral gavage (8 mg mizoribine 
group). In each group, blood samples were collected 
from 5 rats at 0.5, 2 and 4 hours after administering 
mizoribine whilst the blood samples of the remaining 5 
rats were collected 1, 3 and 6 hours after administering 
mizoribine. To minimize the influence of blood loss upon 
the pharmacokinetic analysis, we collected blood three 
times per rat.  The serum concentration of mizoribine 
was determined by high-performance liquid 
chromatography (HPLC) [23]. The simulation values of 
pharmacokinetics analysis were performed with the 
statistical software WinNonlin Ver5.2 (Pharsight 
Corporation, USA) and fitted to the one-compartment 
model. 
 
Statistical analysis 
Results are expressed as means ± standard error (SE) for 
each group. Statistical analysis was performed with 
analysis of variance by Tukey’s post-hoc test. Data 
differences were deemed significant at P<0.05. 
 
 
Results 
Morphologic Examination 
Morphologic changes were assessed by H&E staining. 
A monolayer of mesothelial cells was observed in 
normal rats covering the peritoneal surface without any 
thickening of the peritoneum (Fig. 1a). The appearance 
of the peritoneum of control rats receiving intraperitoneal 
vehicle only (15% ethanol dissolved in saline) was 
similar to that of the normal rats (Fig. 1b). The daily 
intraperitoneal injection of CG for 28 days resulted in 
marked thickening of the submesothelial compact zone 
associated with increased cellularity (Fig. 1c). The 
administration of mizoribine suppressed both the 
thickness of the submesothelial zone and the increased 
cellularity induced by CG (Fig. 1d and 1e). 
Morphological evaluation revealed a significant 
inhibitory effect of mizoribine on CG-induced peritoneal 
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thickening with this anti-fibrotic effect being 
dose-dependent (control group 17.4 ± 1.7×103μm2; CG + 
vehicle group 222.7 ± 8.5×103μm2; CG + mizoribine 2 
mg group 128.5 ± 4.1×103μm2; CG + mizoribine 8 mg 
group 85.8 ± 3.3×103μm2, Fig. 1f ). 
 
Macrophage infiltration 
We examined the peritoneal expression of the 
macrophage marker ED1. ED1+ cells were rarely 
observed in the control group (1.4 ± 0.6 ED1+ cells/10 
fields, Fig. 2a). The number of ED1+ cells in the 
peritoneum was significantly increased in rats receiving 
injections of CG (491.1 ± 34.5 ED1+ cells/10 fields, 
p<0.01, Fig. 2b and 2e) compared with the control group. 
Daily treatment with 2mg of mizoribine significantly 
suppressed macrophage infiltration of the peritoneum 
induced by CG injection compared with the group 
receiving CG and vehicle (189.8 ± 7.7 vs 491.1 ± 34.5 
ED1+ cells/10 fields, p<0.01, Fig. 2c and 2e). In addition, 
the number of ED1+ cells in the peritoneum was further 
decreased in rats treated with 8mg of mizoribine per day 
compared to rats treated with 2mg of mizoribine daily 
thereby indicating a dose-dependent effect (93.0 ± 8.4 vs 
189.8 ± 7.7 ED1+ cells /10 fields, p<0.01, Fig. 2d and 2e). 
The number of ED1+ cells per submesothelial area (mm2) 
was also analyzed and the results were similar to those 
expressed as the number of ED1+ cells per field with 
mizoribine exerting a significant anti-inflammatory and 
therapeutic effect (Table 1). These data suggested that 
the marked reduction in the number of ED1+ 
macrophages was not merely a reflection of reduced 
submesothelial tissue volume. These results demonstrate 
that treatment with mizoribine significantly inhibits 
infiltration of the peritoneum by ED1+ macrophages 
following the administration of CG, with this action 
possibly being related to the potent immunosuppressive 
effect of mizoribine.  
 
Immunohistochemical analysis of type III collagen 
To examine the effects of mizoribine on peritoneal 
fibrosis induced by CG, we next examined the 
expression of type III collagen. Marked expression of 
type III collagen in the submesothelial zone was 
observed in rats receiving CG compared to the control 
group receiving vehicle alone (573.2 ± 28.6 vs 6.6 ± 1.4 
×103 pixels, p<0.01, Fig. 3a, 3b and 3e). Daily treatment 
with 2 mg of mizoribine significantly reduced the 
peritoneal expression of type III collagen induced by CG 
compared to rats receiving CG alone (306.8 ± 15.5 vs 
573.2 ± 28.6 ×103 pixels, P<0.01, Fig. 3c and 3e). In 
addition, the expression of type III collagen in the 
submesothelial zone was further and significantly 
decreased in rats treated with 8mg of mizoribine per day 
compared to rats treated with 2mg of mizoribine per day 
thereby indicating a dose-dependent therapeutic and 
anti-fibrotic effect (181.7 ± 11.8 vs 306.8 ± 15.5 ×103 
pixels, P<0.01, Fig. 3d and 3e). 
 
Immunohistochemical analysis of α-SMA expression 
We also determined the number of α-SMA+ 
myofibroblasts in the peritoneum associated with 
peritoneal fibrosis. In the control group, the expression 
of α-SMA was only observed in vascular smooth muscle 
cells (6.9 ± 2.5 α-SMA+ cells/10 fields, Fig. 4a). In rats 
administered CG, α-SMA expression was found in 
myofibroblasts in addition to vascular smooth muscle 
cells with numerous α-SMA+ myofibroblasts evident in 
the thickened peritoneal tissues (707.8 ± 36.1 α-SMA+ 
cells/10 fields, Fig. 4b). Treatment with mizoribine 
significantly inhibited the increase in peritoneal α-SMA+ 
myofibroblast number induced by CG compared to rats 
administered CG alone (291.0 ± 24.1 vs 707.8 ± 36.1 
α-SMA+ cells/10 fields, P<0.01, Fig. 4c and 4e). The 
increase in the number of α-SMA+ cells in the 
peritoneum was further and significantly suppressed in 
rats treated with 8 mg mizoribine daily compared rats 
 6
treated with 2mg mizoribine (140.8 ± 15.5 vs 291.0 ± 
24.1 α-SMA+ cells/10 fields, P<0.01, Fig. 4d and 4e). 
The number of α-SMA+ cells per submesothelial area 
(mm2) was also determined and similar results were 
obtained (Table 1) thereby indicating that the reduction 
in the number of α-SMA+ cells in mizoribine treated rats 
was not merely a reflection of reduced submesothelial 
tissue volume. 
 
Immunohistochemical analysis of TGF-β 
We next examined the peritoneal expression of the 
profibrotic growth factor TGF-β that is associated with 
peritoneal fibrosis. In the control group, TGF-β+ cells 
were rarely observed (6.0 ± 1.9 TGF-β+ cells/10 fields, 
Fig. 5a) and immunoreactivity for TGF-β was observed 
in the submesothelial area and in the fibrotic layer. The 
number of peritoneal TGF-β+ cells was increased 
markedly in rats receiving CG alone compared to the 
control group (617 ± 27.6 vs 6.0 ± 1.9 TGF-β+ cells/10 
fields, P<0.01, Fig. 5b and 5e). Daily treatment with 2mg 
of mizoribine significantly suppressed the increase in the 
number of peritoneal TGF-β+ cells compared to rats 
administered CG alone (249.4 ± 11.3 vs 617 ± 27.6 
TGF-β+ cells/10 fields, P<0.01, Fig. 5c and 5e). The 
number of peritoneal TGF-β+ cells was further reduced 
in rats treated with 8mg mizoribine daily compared to 
rats receiving 2mg of mizoribine (127.6 ± 7.6 vs 249.4 ± 
11.3 TGF-β+ cells/10 fields, P<0.01, Fig. 5d and 5e). The 
number of TGF-β+ cells per submesothelial area (mm2) 
was also determined and similar results were observed 
(Table 1) suggesting that the reduction in the number of 
TGF-β+ cells was not merely a reflection of reduced 
submesothelial tissue volume. 
 
Immunohistochemical analysis of MCP-1 
We next examined the peritoneal expression of MCP-1, 
a chemotactic factor which attracts monocytes. 
MCP-1+ cells were observed rarely in the control group 
(29.0 ± 11.3 MCP-1+ cells/10 fields, Fig. 6a). The 
number of peritoneal MCP-1+ cells was increased 
markedly in rats receiving CG alone compared to the 
control group (1338.4 ± 102.4 vs 29.0 ± 11.3 
MCP-1+ cells/10 fields, P<0.01, Fig. 6b and 6e). Daily 
treatment with 2mg of mizoribine significantly 
suppressed the increase in the number of peritoneal 
MCP-1+ cells compared to rats administered CG alone 
(476.5 ± 50.4 vs 1338.4 ± 102.4 MCP-1+ cells/10 fields, 
P<0.01, Fig. 6c and 6e). The number of peritoneal 
MCP-1+ cells was further reduced in rats treated with 
8mg mizoribine daily compared to rats receiving 2mg of 
mizoribine (228.3 ± 28.1 vs 476.5 ± 50.4 
MCP-1+ cells/10 fields, P<0.01, Fig. 6d and 6e). The 
number of MCP-1+ cells per submesothelial area (mm2) 
was also determined and similar results were observed 
(Table 1) suggesting that the reduction in the number of 
MCP-1+ cells was not merely a reflection of reduced 
submesothelial tissue volume. 
 
Double staining of ED1 and TGF-β 
We also performed double staining of ED1 and 
TGF-β.  The majority of ED1+ macrophages in the 
submesothelial compact zone showed immunoreactivity 
for TGF-β (Fig. 7), demonstrating colocalisation of ED1 
and TGF-β. 
 
Pharmacokinetic parameters 
The change of serum concentration of mizoribine over 
time is shown in Fig. 8 and the pharmacokinetic profile 
of mizoribine was analysed using this data (Table 2.). 
The time to maximum serum concentration (Tmax) of 
mizoribine was 1.04 hr in the group treated with 2mg 
mizoribine and 1.21 hr in the 8mg mizoribine group. The 
maximum serum concentration (Cmax) of mizoribine 
was 0.514 μg/mL in the group treated with 2mg 
mizoribine and 2.214 μg/mL in the 8mg mizoribine 
group. The elimination half-life (T1/2) of mizoribine was 
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1.42 hr in the group treated with 2mg mizoribine and 
1.68 hr in the 8mg mizoribine group. The area under the 
serum concentration-time curve infinity (AUCinf) of 
mizoribine was 1.61 μg・hr/mL in the group treated with 
2mg mizoribine and 8.46 μg・hr/mL in 8mg mizoribine 
group. 
 
 
Discussion 
In the present study, we demonstrated that 
administration of mizoribine markedly reduced 
macrophage infiltration in the experimental rat model of 
peritoneal fibrosis induced by CG with this effect being 
dose-dependent. Moreover, treatment with mizoribine 
diminished collagen accumulation in the thickened 
submesothelial area. These findings indicate that 
mizoribine might be useful in preventing the progression 
of peritoneal fibrosis and implicate macrophage 
infiltration, at least in part, in the development of 
peritoneal fibrosis. 
The inhibitory effect of mizoribine upon the number 
of ED1+ macrophages in the thickened submesothelial 
area may be mediated via the potent immunosuppressive 
action of mizoribine. Mizoribine inhibits both humoral 
and cellular immunity via the inhibition of de novo 
purine biosynthesis [9]. Sato et al. reported that treatment 
with mizoribine significantly ameliorated 
tubulointerstitial fibrosis and infiltration by macrophages 
and T lymphocytes in rats with unilateral ureteral 
obstruction [18]. Kikuchit et al. also showed mizoribine 
inhibited renal macrophage accumulation and prevented 
the progression of glomerulosclerosis and interstitial 
fibrosis in non-insulin-dependent diabetic rats. [24]. It 
was reported that macrophages can synthesize 
extracellular matrix protein such as collagen and 
fibronectin which may cause fibrosis [25, 26]. In this 
regard, the infiltrating macrophages secrete important 
soluble factors such as TGF-β [27] and it is therefore 
possible that the decrease in submesothelial area caused 
by administration of mizoribine may be associated 
closely with the inhibitory effect upon macrophage 
infiltration.  
Characteristic histological changes of peritoneal 
fibrosis such as thickening of the submesothelial area 
and the accumulation of type III collagen were 
significantly inhibited by treatment with mizoribine. The 
pivotal role of TGF-β1 in the development of peritoneal 
fibrosis results from the effect of TGF-β1 upon human 
peritoneal mesothelial cells (HPMC) including the 
induction of epithelial mesenchymal transition and the de 
novo synthesis of type III collagen [28, 29]. 
Immunohistochemical analysis indicated a significant 
inhibitory effect of mizoribine on the number of TGF-β+ 
 cells in the peritoneum. Thus, the inhibitory effect of 
mizoribine on the accumulation of type III collagen 
induced by administration of CG may be partly mediated 
via its inhibitory effect upon TGF-β expression. 
Immunoreactivity for α-SMA and TGF-β1 was observed 
in the submesothelial area in rats administered CG. 
Treatment with mizoribine suppressed the increase in the 
number of peritoneal α-SMA+ cells in rats administered 
CG in parallel with its inhibitory effect on TGF-β 
expression and accumulation of extracellular matrix. The 
de novo synthesis of α-SMA by HPMC after TGF-β1 
stimulation has been reported [29] and it is possible that 
the therapeutic effect of mizoribine on peritoneal fibrosis 
may partly result from its regulatory role upon the 
conversion of peritoneal mesothelial cells to 
myofibroblasts.  
The expression of MCP-1, a chemotactic factor which 
attracts monocytes, was inhibited significantly by 
treatment with mizoribine. Mizoribine inhibited 
upregulation of chemokines such as MCP-1, as well as 
suppressing the proliferation of macrophages. As 
macrophage accumulation in the thickened 
submesothelial area was suppressed, the production of 
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TGF-β may also have been inhibited, resulting in 
prevention of peritoneal fibrosis. The colocalisation of 
ED1 and TGF-β observed with double immunostaining 
supports this hypothesis. 
For the analysis of immunohistochemical findings, we 
also determined the number of ED1+, α-SMA+ ,TGF-β+ 
and MCP-1+ cells per submesothelial area (mm2). The 
results were similar to the measurement of cell number 
per field thereby demonstrating that the significant 
therapeutic effects of mizoribine did not merely reflect 
the differences in submesothelial thickening between 
experimental groups. 
No adverse events were observed in this study despite 
the fact that the higher dose of mizoribine used was 
greater than the conventional dose of mizoribine used 
(up to 5 mg/kg body weight). Stypinski et al. reported 
that the daily administration of mizoribine up to 12mg/kg 
body weight caused no significant adverse events in 
healthy male volunteers except for a slight elevation in 
serum uric acid [30]. Tanaka et al. reported that a peak 
serum level of mizoribine of at least 2.5-3.0 μg/ml is 
necessary to achieve satisfactory clinical efficacy of the 
drug in the treatment of lupus nephritis [31]. 
Pharmacokinetic analysis of the rats in this study 
indicated that the Cmax was lower than 2.5-3.0 μg/ml 
when the dose of mizoribine administered was 8mg/kg 
body weight. Moreover, rats receiving 8mg mizoribine 
daily exhibited a more marked amelioration in peritoneal 
fibrosis than rats receiving 2mg mizoribine. Therefore, 
the administration of mizoribine at a dose of 8mg/kg 
body weight is optimal for preventing the progression of 
peritoneal fibrosis in rats. 
In the present study, we induced peritoneal fibrosis by 
the intraperitoneal injection of CG. It is true that 
CG-induced peritoneal fibrosis does not fully replicate 
the peritoneal sclerosis or encapsulating peritoneal 
sclerosis observed in patients on long-term PD. However, 
there is not an ideal experimental model that simulates 
long-term PD and CG-induced peritoneal fibrosis 
undoubtedly exhibits key features of peritoneal fibrosis. 
In conclusion, the administration of mizoribine 
prevented the progression of peritoneal fibrosis in a rat 
model. Mizoribine is a potentially useful therapy for 
peritoneal sclerosis in patients undergoing long-term PD. 
As mizoribine has lower nephrotoxicity than other 
immunosuppressive agents, its benefit may be in 
preserving residual renal function of PD patients in 
comparison with other immunosuppressive agents. 
 
 
Acknowledgements 
The authors would like to thank Asahi-Kasei Pharm, 
Tokyo, for conducting the measurements of the blood 
levels of mizoribine. 
 9
References 
 
1. Selgas R, Fernandez-Reyes MJ, Bosque E, Bajo MA, 
Borrego F, Jimenez C, Del Peso G, De Alvaro F: 
Functional longevity of the human peritoneum: how long 
is continuous peritoneal dialysis possible? Results of a 
prospective medium long-term study. Am J Kidney Dis 
1994; 23: 64-73.  
2. Davies SJ, Bryan J, Phillips L, Russell GI: Longitudinal 
changes in peritoneal kinetics: the effects of peritoneal 
dialysis and peritonitis. Nephrol Dial Transplant 1996; 
11: 498-506. 
3. Ito T, Yorioka N: Peritoneal damage by peritoneal dialysis 
solutions. Clin Exp Nephrol 2008; 12: 243-249. 
4. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon 
M, Newman GR, Mackenzie RK, Williams GT: 
Morphologic changes in the peritoneal membrane of 
patients with renal disease. J Am Soc Nephrol 2002; 13: 
470-479. 
5. Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, 
Jablokow VR, Iwatsuki S, Geis WP, Hano JE: Sclerotic 
thickening of the peritoneal membrane in maintenance 
peritoneal dialysis patients. Arch Intern Med 1980; 140: 
1201-1203. 
6. Kawanishi H, Moriishi M: Encapsulating peritoneal 
sclerosis: prevention and treatment. Perit Dial Int 2007; 
27 Suppl 2: S289-92. 
7. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, 
Yamauchi S, Margolin S: Preventive effect of pirfenidone 
against experimental sclerosing peritonitis on rats. Exp 
Toxicol Pathol 1995; 47: 287-291. 
8. Mishima Y, Miyazaki M, Abe K, Ozono Y, Shioshita K, 
Xia Z, Harada T, Taguchi T, Koji T, Kohno S: Enhanced 
expression of heat shock protein 47 in rat model of 
peritoneal fibrosis. Perit Dial Int 2003; 23: 14-22. 
9. Koyama H, Tsuji M: Genetic and biochemical studies on 
the activation and cytotoxic mechanism of bredinin, a 
potent inhibitor of purine biosynthesis in mammalian cells. 
Biochem Pharmacol 1983; 32: 3547-3553 
10. Kusumi T, Tsuda M, Katsunuma T, Yamamura M: Dual 
inhibitory effect of bredinin. Cell Biochem Funct 1989; 7: 
201-204. 
11. Ishikawa H: Mizoribine and mycophenolate mofetil. Curr 
Med Chem 1999; 6: 575-597. 
12. Akiyama T, Okazaki H, Takahashi K, Hasegawa A, 
Tanabe K, Uchida K, Takahara S, Toma H: Links 
Mizoribine in combination therapy with tacrolimus for 
living donor renal transplantation: analysis of a 
nationwide study in Japan. Transplant Proc 2005; 37: 
843-845. 
13. Tanaka E, Inoue E, Kawaguchi Y, Tomatsu T, Yamanaka 
H, Hara M, Kamatani N: Acceptability and usefulness of 
mizoribine in the management of rheumatoid arthritis in 
methotrexate-refractory patients and elderly patients, 
based on analysis of data from a large-scale observational 
cohort study. Mod Rheumatol 2006; 16: 214-219. 
14. Nakayamada S, Saito K, Umehara H, Ogawa N, Sumida T, 
Ito S, Minota S, Nara H, Kondo H, Okada J, Mimori T, 
Yoshifuji H, Sano H, Hashimoto N. Sugai S, Tanaka Y: 
Efficacy and safety of mizoribine for the treatment of 
Sjögren's syndrome: a multicenter open-label clinical trial. 
Mod Rheumatol 2007; 17: 464-469. 
15. Tanaka H, Tsugawa K, Tsuruga K, Suzuki K, Nakahata T, 
Ito E, Waga S: Mizoribine for the treatment of lupus 
nephritis in children and adolescents. Clin Nephrol 2004; 
62: 412-417. 
16. Honda M: Nephrotic syndrome and mizoribine in children. 
Pediatr Int 2002; 44: 210-216. 
17. Sakai T, Kawamura T, Shirasawa T: Mizoribine improves 
renal tubulointerstitial fibrosis in unilateral ureteral 
obstruction (UUO)-treated rat by inhibiting the infiltration 
of macrophages and the expression of alpha-smooth 
muscle actin. J Urol 1997; 158: 2316-2322. 
18. Sato N, Shiraiwa K, Kai K, Watanabe A, Ogawa S, 
Kobayashi Y, Yamagishi-Imai H, Utsunomiya Y, Mitarai 
T: Mizoribine ameliorates the tubulointerstitial fibrosis of 
 10
obstructive nephropathy. Nephron 2001; 89: 177-185. 
19. Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, 
Harada T, Ozono Y, Koji T, Kohno S: Antisense 
oligonucleotides against collagen-binding stress protein 
HSP47 suppress peritoneal fibrosis in rats. Kidney Int 
2003; 64: 887-896.  
20. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, 
Mizuta Y, Harada T, Ozono Y, Koji T, Kohno S: 
TNP-470, an angiogenesis inhibitor, suppresses the 
progression of peritoneal fibrosis in mouse experimental 
model. Kidney Int 2004; 66: 1677-1685. 
21. Doi S, Masaki T, Arakawa T, Takahashi S, Kawai T, 
Nakashima A, Naito T, Kohno N, Yorioka N: Protective 
effects of peroxisome proliferator-activated receptor 
gamma ligand on apoptosis and hepatocyte growth factor 
induction in renal ischemia-reperfusion injury. 
Transplantation 2007; 84: 207-213. 
22. Hirai T, Masaki T, Kuratsune M, Yorioka N, Kohno N: 
PDGF receptor tyrosine kinase inhibitor suppresses 
mesangial cell proliferation involving STAT3 activation. 
Clin Exp Immunol 2006; 144: 353-361. 
23. Hosotsubo H, Takahara S, Taenaka N: Simplified 
high-performance liquid chromatographic method for 
determination of mizoribine in human serum. J 
Chromatography 1988; 432: 340-345 
24. Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, 
Hyodo N, Suzuki S, Miura S: Mizoribine reduces renal 
injury and macrophage infiltration in 
non-insulin-dependent diabetic rats. Nephrol Dial 
Transplant 2005; 20: 1573-81 
25. Vaage J, Lindblad WJ: Production of collagen type I by 
mouse peritoneal macrophages. J Leukoc Biol 1990; 48: 
274-280. 
26. Nathan CF: Secretory products of macrophages. J Clin 
Invest 1987; 79: 319-326. 
27. Diamond JR, Kees-Folts D, Ding G, Frye JE, Restrepo 
NC: Macrophages, monocyte chemoattractant peptide-1, 
and TGF-beta 1 in experimental hydronephrosis. Am J 
Physiol 1994; 266: F926-933. 
28. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, 
West-Mays JA, Kelly MM: Transient overexpression of 
TGF-β1 induces epithelial mesenchymal transition in the 
rodent peritoneum. J Am Soc Nephrol 2005; 16: 425–436. 
29. Yang AH, Chen JY, Lin JK: Myofibroblastic conversion of 
mesothelial cells. Kidney Int 2003; 63: 1530–1539. 
30. Stypinski D, Obaidi M, Combs M, Weber M, Stewart AJ, 
Ishikawa H: Safety, tolerability and pharmacokinetics of 
higher-dose mizoribine in healthy male volunteers. Br J 
Clin Pharmacol 2007; 63: 459-468. 
31. Tanaka H, Tsugawa K, Nakahata T, Kudo M, Suzuki K, 
Ito E: Implication of the peak serum level of mizoribine 
for control of the serum anti-dsDNA antibody titer in 
patients with lupus nephritis. Clin Nephrol 2005; 63: 
417-422. 
 11
Tables 
 
Table 1. Morphometric analysis of immunohistochemical findings 
  CG + vehicle  CG + 2 mg mizoribine CG + 8 mg mizoribine 
ED1+ cells (/mm2)  88.3±5.1 59.0±1.3a 43.1±3.1a,b 
α-SMA+ cells (/ mm2) 128.0±7.2 89.9±5.6a 65.6±6.7a,b 
TGF-β+ cells (/ mm2) 112.6±8.0 78.2±4.8a 59.5±2.2a,b 
MCP-1+ cells (/ mm2) 239.5±15.0 151.1±11.5a 119±19.7a,b 
 
All values are mean ± SE. n=8 in each group. The number of positive cells was counted in 10 fields and represented as per mm2 of 
submesothelial fibrotic tissue by measuring the fibrotic area using NIS-Elements D software. aP<0.05 vs CG + vehicle group. 
bP<0.05 vs CG + 2 mg mizoribine group. 
 
 
 
Table 2. Pharmacokinetic parameter (one compartment model). 
  Mizoribine 2mg/kg Mizoribine 8mg/kg 
Tmax (hr) 1.04 1.21 
Cmax (μg/mL) 0.514 2.214 
T1/2   (hr) 1.42 1.68 
AUCinf (μg・hr/mL) 1.61 8.46 
 
Pharmacokinetics analysis was performed with the statistical software WinNonlin Ver5.2 (Pharsight Corporation, USA). Cmax, the 
maximum concentration of mizoribine in serum; Tmax, the time to maximum concentration of mizoribine in serum; T1/2, 
elimination half-life of mizoribine; AUCinf, the area under the serum concentration-time curve infinity of mizoribine.  
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